ClinicalTrials.gg
CompletedNCT03344640Updated Oct 8, 2021Results posted

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

A Phase 2 interventional study of secukinumab and Placebo in Tendinopathy, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 99 studies in Tendinopathy with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Tendinopathy · United States.

Enrollment
21st of 89
96 · median 40
Started
2017
with 9 others
Phase 2
11 of 99
none open now
Registered
46th of 99
by date
Lead sponsor
4 of 99
Novartis Pharmaceuticals

Among the 99 studies in Tendinopathy with a site in United States, this one is the 21st largest by enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2017, is one of 11 in phase 2, and was the 46th registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

15 of the 99 studies in Tendinopathy with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Tendinopathy with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease and refractory to NSAIDs/acetaminophen, physiotherapy or corticosteroids.

The study consisted of a 4-week screening period, a 2-week run-in period, a 12-week treatment period and a 12-week follow-up period after last treatment. The population consisted of patients with unilateral overuse (non-systemic inflammatory) shoulder tendinopathy, 18 - 65 years of age.

Safety assessments included physical examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), adverse event and serious adverse event monitoring.

03

Conditions studied

  • Tendinopathy

Browse trials for

Keywords

  • Overuse tendinopathy
  • shoulder
  • rotator cuff
  • IL-17A-Ab
  • AIN457X
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-lactating female patients 18 to 65 years of age at randomization
  2. Presence of unilateral rotator cuff tendinopathy with:

    1. Symptoms present ≥6 weeks, but \<12 months prior to randomization
    2. Tendinopathy with no more than a 50% tear as established by ultrasound at screening (historic data acceptable if not older than 3 months) and MRI at baseline: Sein MRI tendinopathy scoring system grade I-III; with no tear or partial tear [maximum 50% tendon thickness (Bauer tendon thickness score maximum 2); AP length maximum 10 mm (Bauer tendon length score max 2)]. Maximum 50% of patients with partial tear
    3. Pain in the affected shoulder (at rest or on movement) on at least 3 days out of 7 days in the past week prior to baseline and a score of ≥4 out of 10 on a VAS pain scale
    4. Positive "Painful Arc Test" on examination and/or nightly pain in the affected shoulder on at least 4 out of 7 days in the past week prior to baseline
  3. The rotator-cuff tendinopathy must have been to standard treatment, including NSAIDs and physiotherapy

Exclusion criteria

Exclusion Criteria:

  1. Rheumatologic, inflammatory diseases, including but not limited to: PsA, AS and RA 2. Previous shoulder surgery in affected shoulder 3. History of adhesive capsulitis/frozen shoulder or calcification in the tendon (in affected or contralateral shoulder) confirmed by X-Ray, historic X-Rays can be used if performed within 3 months of baseline 4. Symptomatic osteoarthritis of the shoulder (gleno-humeral, acromioclavicular) (in affected or contralateral shoulder confirmed by X-Ray, historic X-Rays can be used if performed within 3 months of baseline 5. Neck conditions, including but not limited to cervical spine syndrome, which in the opinion of the investigator, may explain the patient's symptoms 6. Previous rich plasma injections within the last 12 months prior to randomization 7. Previous treatment with any cell-depleting therapies including but not limited to anti- CD20, agents (e.g. Campath, anti-CD4, anti-CD5, anti-CD3, anti-CD19) 8. Previous exposure to any biologic immunomodulating agents, including but not limited to TNFalpha inhibitors (including, but not limited to adalimumab, infliximab), or biologics targeting IL-17 (including, but not limited to secukinumab, ixekizumab or brodalumab) or the IL-17 receptor within the last 12 months prior to baseline 9. Any intraarticular/subacromial treatment within 8 weeks prior to randomization and more than 3 injections for the current tendinopathy. Oral, intramuscular or i.v. corticosteroid treatment within the last 12 months prior to randomization

-

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    secukinumab

    AIN457 300 mg subcutaneously (s.c.) for 12 weeks

    Drug: secukinumab

  • Placebo comparator
    Placebo

    Placebo subcutaneously for 12 weeks

    Other: Placebo

Interventions

  • AIN457 300 mg subcutaneously for 12 weeks

    Also known as: AIN457

  • OtherPlacebo

    Placebo to match AIN457 subcutaneously for 12 weeks

06

What researchers measure

Primary outcomes

  1. The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14

    WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best. All Patients - Statistical analysis results of WORC scores at Week 14

    Time frame: Week 14 (Day 99)

Secondary outcomes

  1. The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients

    WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)

    Time frame: Days 15, 29, 57, 85, 127, and End of Study

  2. Disability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time

    Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable). The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome

    Time frame: Days 15, 29, 57, 85, 99, 127, and End of Study

  3. American Shoulder and Elbow Surgeons (ASES) Score Over Time

    Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).

    Time frame: Days 15, 29, 57, 85, 99, 127, and End of Study

  4. Your Health Today Score Over Time

    Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).

    Time frame: Days 15, 29, 57, 85, 99, 127, and End of Study

  5. EQ-5D-5L Index Score Over Time

    Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.

    Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study

  6. Pain Score Over Time Using a VAS Scale

    Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between "no pain" and "worst pain". The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).

    Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study

  7. Patient Global Assessment (PGA) Score Over Time Using a VAS Scale

    The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from "no activity" to "most active" in the last 24 hours. The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).

    Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study

  8. Physician Global Assessment (PhGA) Score Using a VAS Scale Over Time

    Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours). The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).

    Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study

  9. Pharmacokinetics - Cmin

    Mean trough concentrations Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume) Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS

    Time frame: Days 1, 29, 85 and EoS (End of Study)

  10. Immunogenicity Assessment - Treatment Emergent ADAs

    Number of Participants with Treatment emergent Anti-secukinumab antibodies

    Time frame: Day 1 and EoS

  11. Number of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores

    Assessment of structural changes in the rotator cuff tendinopathy over time The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis. In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.

    Time frame: Baseline and Day 99

07

Results

Posted Dec 9, 2020
Limitations and caveats
In general "End of Study" is Day 169 (week 24). But in the study it was handled in a way, that whenever a subject discontinued the last visit was the EoS visit.

Participant flow

Of all patients randomized (N= 98; 100%) in the study, a total of 96 patients (98%) were dosed (49 patients in the secukinumab 300 mg group and 47 patients in the placebo group)

Participant flow — Overall Study
MilestoneSecukinumabPlacebo
Started4947
Completed4644
Not completed33
Withdrew: Adverse event10
Withdrew: Physician decision11
Withdrew: Withdrawal by subject12
Follow-up Epoch
Participant flow — Follow-up Epoch
MilestoneSecukinumabPlacebo
Started4644
Completed4642
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryThe Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14

WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best. All Patients - Statistical analysis results of WORC scores at Week 14

Time frame:
Week 14 (Day 99)
Reported as:
Number · Scores on a scale
The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14
Scores on a scaleSecukinumabPlacebo
The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 1437.00 (30.10 to 43.90)37.77 (30.40 to 45.15)
Statistical analysis
  • Secukinumab vs Placebo · LS mean · p = 0.875 · Mean difference (final values): -0.77 · 90% CI -8.84 to 7.30LS mean change from baseline in WORC total percentage score
SecondaryThe Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients

WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)

Time frame:
Days 15, 29, 57, 85, 127, and End of Study
Reported as:
Number · Scores on a scale
The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients
Scores on a scaleSecukinumabPlacebo
Day 1512.39 (6.99 to 17.79)8.42 (2.66 to 14.18)
Day 2922.35 (16.38 to 28.32)19.49 (13.11 to 25.86)
Day 5728.74 (22.19 to 35.29)30.11 (23.08 to 37.13)
Day 8534.86 (28.18 to 41.53)33.48 (26.35 to 40.61)
Day 12741.86 (34.96 to 48.77)38.50 (31.12 to 45.88)
End of Study43.41 (36.21 to 50.61)40.97 (33.27 to 48.66)
Statistical analysis
  • Secukinumab vs Placebo · LS mean · p = 0.190 · Difference and 90% ci versus placebo: 3.97 · 90% CI -1.03 to 8.97LS mean change from baseline in WORC total percentage score
  • Secukinumab vs Placebo · LS Mean · Difference and 90% ci versus placebo: 3.97 · 90% CI -3.39 to 9.11LS mean change from baseline in WORC total percentage score
  • Secukinumab vs Placebo · LS Mean · p = 0.761 · Difference and 90% ci versus placebo: 0.761 · 90% CI -8.81 to 6.08LS mean change from baseline in WORC total percentage score
  • Secukinumab vs Placebo · LS Mean · p = 0.765 · Difference and 90% ci versus placebo: 0.765 · 90% CI -6.27 to 9.03LS mean change from baseline in WORC total percentage score
  • Secukinumab vs Placebo · LS Mean · p = 0.491 · Difference and 90% ci versus placebo: 0.491 · 90% CI -4.73 to 11.45LS mean change from baseline in WORC total percentage score
  • Secukinumab vs Placebo · LS Mean · p = 0.639 · Difference and 90% ci versus placebo: 2.44 · 90% CI -6.19 to 11.07LS mean change from baseline in WORC total percentage score
SecondaryDisability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time

Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable). The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome

Time frame:
Days 15, 29, 57, 85, 99, 127, and End of Study
Reported as:
Number · Scores on a scale
Disability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time
Scores on a scaleSecukinumabPlacebo
Day 15-11.64 (-16.14 to -7.14)-8.23 (-13.02 to -3.44)
Day 29-18.31 (-23.20 to -13.41)-16.95 (-22.18 to -11.73)
Day 57-22.43 (-27.55 to -17.30)-24.01 (-29.49 to -18.52)
Day 85-28.14 (-33.55 to -22.73)-27.22 (-32.98 to -21.45)
Day 99-29.45 (-34.72 to -24.19)-30.69 (-36.30 to -25.07)
Day 127-32.86 (-38.26 to -27.46)-31.99 (-37.75 to -26.23)
End of Study-33.89 (-39.27 to -28.50)-35.40 (-41.13 to -29.67)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.735 (Difference and 90% CI versus placebo) · Difference and 90% ci versus placebo: 1.23 · 90% CI -4.81 to 7.28LS mean change from baseline in QuickDASH total score
  • Secukinumab vs Placebo · LS Mean · p = 0.689 · Difference and 90% ci versus placebo: 1.51 · 90% CI -4.76 to 7.79LS mean change from baseline in QuickDASH total score
SecondaryAmerican Shoulder and Elbow Surgeons (ASES) Score Over Time

Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).

Time frame:
Days 15, 29, 57, 85, 99, 127, and End of Study
Reported as:
Number · Scores on a scale
American Shoulder and Elbow Surgeons (ASES) Score Over Time
Scores on a scaleSecukinumabPlacebo
Day 158.66 (3.98 to 13.33)5.26 (0.26 to 10.25)
Day 2917.53 (12.35 to 22.71)14.37 (8.82 to 19.92)
Day 5724.15 (18.34 to 29.96)22.56 (16.31 to 28.81)
Day 8530.50 (24.51 to 36.50)26.97 (20.51 to 33.43)
Day 9931.29 (25.28 to 37.31)27.79 (21.33 to 34.26)
Day 12734.92 (28.80 to 41.05)32.94 (26.33 to 39.56)
End of Study37.29 (30.97 to 43.62)36.15 (29.33 to 42.97)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.411 · Difference and 90% ci vesus placebo: 3.50 · 90% CI -3.54 to 10.54LS mean change from baseline in ASES total percentage score
  • Secukinumab vs Placebo · LS Mean · p = 0.804 · Difference and 90% ci versus placebo: 1.14 · 90% CI -6.50 to 8.78LS mean change from baseline in ASES total percentage score
SecondaryYour Health Today Score Over Time

Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).

Time frame:
Days 15, 29, 57, 85, 99, 127, and End of Study
Reported as:
Number · Scores on a scale
Your Health Today Score Over Time
Scores on a scaleSecukinumabPlacebo
Day 15-0.22 (-4.02 to 3.58)0.02 (-4.02 to 4.07)
Day 293.27 (-0.71 to 7.25)3.56 (-0.69 to 7.81)
Day 573.19 (-1.07 to 7.45)9.02 (4.45 to 13.59)
Day 857.36 (2.84 to 11.89)7.79 (2.96 to 12.62)
Day 998.75 (4.13 to 13.38)10.01 (5.09 to 14.94)
Day 1279.55 (5.29 to 13.80)13.59 (9.05 to 18.13)
End of Study10.22 (4.84 to 15.60)12.13 (6.36 to 17.89)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.706 · Difference and 90% ci versus placebo: -1.26 · 90% CI -6.81 to 4.29LS Mean change from baseline in Your Health Today Score at day 99
  • Secukinumab vs Placebo · LS Mean · p = 0.647 · Difference and 90% ci versus placebo: -1.90 · 90% CI -8.79 to 4.99LS mean change from baseline in Your Health Today score
SecondaryEQ-5D-5L Index Score Over Time

Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.

Time frame:
Days 15, 29, 57, 85, 99, 127 and End of Study
Reported as:
Number · Scores on a scale
EQ-5D-5L Index Score Over Time
Scores on a scaleSecukinumabPlacebo
Day 150.07 (0.05 to 0.10)0.04 (0.01 to 0.07)
Day 290.10 (0.07 to 0.13)0.09 (0.05 to 0.12)
Day 570.12 (0.09 to 0.15)0.11 (0.08 to 0.15)
Day 850.16 (0.13 to 0.19)0.14 (0.10 to 0.18)
Day 990.16 (0.13 to 0.20)0.15 (0.11 to 0.19)
Day 1270.19 (0.15 to 0.23)0.17 (0.13 to 0.21)
End of Study0.19 (0.16 to 0.23)0.18 (0.14 to 0.22)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.613 · Difference and 90% ci versus placebo: 0.01 · 90% CI -0.03 to 0.06LS mean change from baseline in EQ-5D-5L Index score
  • Secukinumab vs Placebo · LS Mean · p = 0.740 · Difference and 90% ci versus placebo: 0.02 · 90% CI -0.04 to 0.06LS mean change from baseline in EQ-5D-5L Index score
SecondaryPain Score Over Time Using a VAS Scale

Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between "no pain" and "worst pain". The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).

Time frame:
Days 15, 29, 57, 85, 99, 127 and End of Study
Reported as:
Number · Scores on a scale
Pain Score Over Time Using a VAS Scale
Scores on a scaleSecukinumabPlacebo
Day 15-12.11 (-19.52 to -4.70)-9.50 (-17.30 to -1.71)
Day 29-26.04 (-33.97 to -18.11)-23.13 (-31.52 to -14.74)
Day 57-35.52 (-43.67 to -27.37)-32.83 (-41.52 to -24.15)
Day 85-42.63 (-50.88 to -34.38)-37.97 (-46.74 to -29.21)
Day 99-46.11 (-54.10 to -38.12)-40.56 (-49.00 to -32.11)
Day 127-49.44 (-57.45 to -41.44)-45.27 (-53.75 to -36.79)
End of Study-52.23 (-60.31 to -44.14)-50.74 (-59.40 to -42.08)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.281 · Difference and 90% ci versus placebo: -5.55 · 90% CI -14.07 to 2.97LS MMean CFB (90% CI)
  • Secukinumab vs Placebo · LS Mean · p = 0.780 · Difference and 90% ci versus placebo: -1.49 · 90% CI -10.33 to 7.35LS Mean CFB (90% CI)
SecondaryPatient Global Assessment (PGA) Score Over Time Using a VAS Scale

The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from "no activity" to "most active" in the last 24 hours. The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).

Time frame:
Days 15, 29, 57, 85, 99, 127 and End of Study
Reported as:
Number · Scores on a scale
Patient Global Assessment (PGA) Score Over Time Using a VAS Scale
Scores on a scaleSecukinumabPlacebo
Day 15-6.33 (-13.44 to 0.79)-8.09 (-15.79 to -0.38)
Day 29-22.25 (-29.68 to -14.82)-16.38 (-24.43 to -8.33)
Day 57-29.40 (-37.06 to -21.74)-25.69 (-34.04 to -17.34)
Day 85-37.57 (-45.01 to -30.12)-31.75 (-39.79 to -23.72)
Day 99-38.43 (-45.88 to -30.97)-35.10 (-43.14 to -27.07)
Day 127-43.78 (-51.23 to -36.33)-38.32 (-46.37 to -30.26)
End of Study-47.72 (-55.15 to -40.28)-39.43 (-47.45 to -31.40)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.489 · Difference and 90% ci versus placebo: -3.32 · 90% CI -11.28 to 4.64LS Mean change from baseline in VAS score
  • Secukinumab vs Placebo · LS Mean · p = 0.087 · Difference and 90% ci versus placebo: -8.29 · 90% CI -16.26 to -0.32LS Mean change from baseline in VAS score
SecondaryPhysician Global Assessment (PhGA) Score Using a VAS Scale Over Time

Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours). The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).

Time frame:
Days 15, 29, 57, 85, 99, 127 and End of Study
Reported as:
Number · Score on a scale
Physician Global Assessment (PhGA) Score Using a VAS Scale Over Time
Score on a scaleSecukinumabPlacebo
Day 15-13.99 (-20.22 to -7.75)-9.11 (-15.80 to -2.42)
Day 29-25.01 (-31.51 to -18.50)-19.42 (-26.42 to -12.43)
Day 57-30.78 (-37.57 to -23.99)-27.83 (-35.13 to -20.53)
Day 85-33.42 (-40.68 to -26.16)-37.88 (-45.66 to -30.11)
Day 99-35.72 (-42.66 to -28.79)-41.73 (-49.15 to -34.31)
Day 127-41.72 (-48.32 to -35.12)-44.18 (-51.28 to -37.08)
End of Study-44.64 (-51.86 to -37.41)-44.26 (-52.02 to -36.51)
Statistical analysis
  • Secukinumab vs Placebo · LS Mean · p = 0.210 · Difference and 99% cl versus placebo: 6.10 · 90% CI -1.90 to 13.91LS Mean CFB (90% CI)
  • Secukinumab vs Placebo · LS Mean · p = 0.942 · Difference and 90% ci versus placebo: -0.37 · 90% CI -8.86 to 8.11LS Mean CFB (90% CI)
SecondaryPharmacokinetics - Cmin

Mean trough concentrations Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume) Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS

Time frame:
Days 1, 29, 85 and EoS (End of Study)
Reported as:
Mean · ug/mL
Pharmacokinetics - Cmin
ug/mLSecukinumab
Mean trough concentration after first 4 wkly doses90.4 ± 30.7
Week 1213.2 ± 6.67
SecondaryImmunogenicity Assessment - Treatment Emergent ADAs

Number of Participants with Treatment emergent Anti-secukinumab antibodies

Time frame:
Day 1 and EoS
Reported as:
Number · Participants
Immunogenicity Assessment - Treatment Emergent ADAs
ParticipantsSecukinumabPlacebo
Day 101
End of Study00
SecondaryNumber of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores

Assessment of structural changes in the rotator cuff tendinopathy over time The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis. In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.

Time frame:
Baseline and Day 99
Reported as:
Number · participants
Number of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores
participantsSecukinumabPlacebo
Baseline grade 13125
Baseline grade 21110
Baseline grade 333
Day 99 grade 13126
Day 99 grade 2119
Day 99 grade 333

Adverse events

Collected over Approximately 40 weeks: 15 Dec 2017 through 17 Oct 2019. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 300 mg s.c.0/49 (0%)0/49 (0%)36/49 (73.5%)
Placebo0/47 (0%)0/47 (0%)34/47 (72.3%)
Most frequent other events
Showing 10 of 100
Most frequent other events
EventAIN457 300 mg s.c.Placebo
NasopharyngitisInfections and infestations8/495/47
HeadacheNervous system disorders7/497/47
NauseaGastrointestinal disorders6/495/47
Upper respiratory tract infectionInfections and infestations2/494/47
Back painMusculoskeletal and connective tissue disorders1/494/47
NeutropeniaBlood and lymphatic system disorders3/491/47
Fungal skin infectionInfections and infestations3/490/47
Musculoskeletal painMusculoskeletal and connective tissue disorders3/491/47
Neck painMusculoskeletal and connective tissue disorders3/491/47
FatigueGeneral disorders1/492/47

Baseline characteristics

The safety analysis set (SAS) included all subjects that received any study drug.

Age, Continuous
Age, Continuous(years)SecukinumabPlaceboTotal
Mean44.8 ± 11.5149.1 ± 10.5646.9 ± 11.20
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabPlaceboTotal
Female172340
Male322456
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SecukinumabPlaceboTotal
Asian101
Black or African American314
White434588
Unknown101
Other112
08

Study locations

12 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85053, United States
  • Novartis Investigative Site
    La Mesa, California 91942, United States
  • Novartis Investigative Site
    Clearwater, Florida 33765, United States
  • Novartis Investigative Site
    Miami Lakes, Florida 33014, United States
  • Novartis Investigative Site
    Tampa, Florida 33603, United States
  • Novartis Investigative Site
    Brno, Czech Republic 66250, Czechia
  • Novartis Investigative Site
    Kolin, Czech Republic 280 02, Czechia
  • Novartis Investigative Site
    Praha, Czechia
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Hamburg, 22415, Germany
  • Novartis Investigative Site
    Leiden, 2333 CL, Netherlands
  • Novartis Investigative Site
    Glasgow, G51 4TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Aug 2019, 19 months.

Results were first posted in Dec 2020, 1 year 4 months after primary completion. A results delay was requested in Feb 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 17, 2017
StartActual
Dec 15, 2017
Primary completionActual
Aug 2, 2019
CompletionActual
Oct 17, 2019
Results delay requested
Feb 17, 2020
Results first posted
Dec 9, 2020
Last update
Oct 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03344640
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Dec 15, 2017
Primary completion
Aug 2, 2019
Completion
Oct 17, 2019
Results posted
Dec 9, 2020
Last update
Oct 8, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion